The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictors of outcome for pemetrexed (Pem) in metastatic NSCLC (mNSCLC).
Cortney Vanderbilt Jones
No relevant relationships to disclose
Lingling Du
No relevant relationships to disclose
Paul Elson
No relevant relationships to disclose
Tarek Mekhail
Honoraria - Lilly
Nathan A. Pennell
Consultant or Advisory Role - Oncogenex; Teva
Nooshin Hashemi Sadraei
No relevant relationships to disclose